Telehealth ADHD Prescribing: What Psychiatrists Can Do in Pennsylvania

If you’re a psychiatrist or PMHNP considering telehealth ADHD care, you’re probably asking: Can I legally prescribe Adderall or other stimulants through a video visit? The short answer in 2026: Yes — for now. But the longer answer involves federal waivers, state-by-state scope differences, and a regulatory landscape that’s still evolving.

Let’s cut through the confusion. Whether you’re an established psychiatrist looking to add telehealth patients or a PMHNP navigating prescriptive authority in your state, this guide explains exactly what you can do, what the laws say, and what to watch for as regulations shift.

The Federal Framework: Telehealth Prescribing for Controlled Substances

ADHD medications like Adderall, Ritalin, and Vyvanse are Schedule II controlled substances. Under the Ryan Haight Act (2008), prescribing Schedule II drugs via telemedicine technically required at least one in-person exam. That changed during COVID-19.

The DEA waived the in-person requirement during the pandemic, allowing psychiatrists to initiate stimulant prescriptions entirely through telehealth. This flexibility was supposed to expire multiple times, but has been extended repeatedly. As of February 2026, these telehealth flexibilities run through December 31, 2025 — meaning providers can still prescribe ADHD medications to new patients via video without an initial face-to-face visit.

Here’s what matters for your practice:

• Through end of 2025: You can conduct a comprehensive video evaluation and e-prescribe stimulants to new ADHD patients without violating federal law
• After 2025: Uncertain. Congress and the DEA are debating permanent rules or another extension
• What to do now: Practice as permitted, but have a contingency plan (partnerships with local clinics for in-person exams, or focus on established patients if rules revert)

The takeaway: Federal law currently supports telehealth ADHD prescribing. But keep your eye on DEA announcements — this could change in 2026 if Congress doesn’t act.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What Psychiatrists Can Do: Full Authority, No Supervision Required

If you’re a psychiatrist (MD/DO), your scope is straightforward:

You have unrestricted authority to prescribe ADHD medications in every state. No physician oversight. No collaborative agreements. No quantity limits beyond standard DEA rules (30-day supplies, no refills on Schedule II, PDMP checks).

In telehealth, this means:

• You can diagnose ADHD via comprehensive video assessment
• You can initiate stimulant medication for new patients (under current federal flexibility)
• You can manage ongoing medication adjustments through follow-up video visits
• You can practice across state lines if you hold licenses in those states

Clinical capabilities via telehealth: You’re not clinically limited. ADHD diagnosis relies on history, standardized rating scales (ASRS, Conners), and behavioral observation — all achievable through video. For vitals monitoring (since stimulants affect BP/HR), ask patients to use home monitoring or get readings from their primary care provider. Many psychiatrists have patients purchase a basic BP cuff or use pharmacy machines between visits.

The only thing you can’t do remotely is a hands-on physical exam, but that’s rarely needed for ADHD management.

PMHNPs: It Depends Where You Practice

If you’re a Psychiatric Mental Health Nurse Practitioner, your prescribing authority for ADHD medications varies dramatically by state. This isn’t about your competency — it’s purely regulatory.

States Where PMHNPs Have Full or Near-Full Authority:

New York: After completing 3,600 hours (~2 years) under physician mentorship, you can practice independently and prescribe all ADHD medications without supervision. During your first two years, you’ll need a collaborative agreement but can still prescribe stimulants within that framework.

Illinois: Complete 4,000 clinical hours plus 250 hours of additional training, and you qualify for Full Practice Authority. Once granted, you can prescribe ADHD stimulants independently. Before that, you need a written collaborative agreement that delegates Schedule II authority.

California: Transitioning. If you’re an experienced NP with ≥3 years (4,600 hours), you can apply for independent practice status (104 NP certification). You’ll also need to complete a specialized pharmacology course for Schedule II authority. New grads still require physician supervision.

States With Significant Restrictions:

Texas: Here’s the hard truth — Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings, with narrow exceptions (hospitalized patients, hospice, or terminal illness). Even with a collaborative agreement, you cannot write routine Adderall prescriptions for an outpatient ADHD patient in Texas. Only physicians can do this.

What this means: In Texas telehealth practices, PMHNPs typically handle therapy, non-stimulant medications (like atomoxetine or guanfacine), or initial assessments — but a psychiatrist must prescribe stimulants.

Florida: You need a collaborative protocol with a psychiatrist. Florida limits NP-prescribed Schedule II drugs to 7-day supplies — except for psychiatric medications. As a certified ‘psychiatric nurse’ working under a psychiatrist’s protocol, you can prescribe 30-day supplies of ADHD stimulants. But you’re not independent; you need that physician relationship.

Pennsylvania: Requires physician collaboration. More importantly, PA limits NPs to prescribing only 72 hours of Schedule II medication initially for new patients, then 30-day supplies for ongoing care. In practice, this means the collaborating psychiatrist often writes the first prescription, then you handle monthly refills.

The Bottom Line for NPs:

Check your state’s specific rules before joining a telehealth platform. In states like NY, IL, and (soon) CA, experienced PMHNPs can run independent ADHD practices. In TX, FL, and PA, you’ll need a physician partner or be limited to certain aspects of care.

State-Specific Telehealth Rules You Should Know

Beyond scope of practice, several states have telehealth-specific prescribing rules:

Florida explicitly permits telehealth prescribing of Schedule II stimulants for psychiatric disorders — ADHD qualifies. This was written into Florida’s telehealth law to distinguish mental health treatment (allowed) from pain management (restricted).

Texas requires video — you cannot prescribe controlled substances via audio-only calls. The encounter must be live, synchronous video to meet standard of care.

New York mandates checking the Prescription Drug Monitoring Program (I-STOP) before every controlled substance prescription. All prescriptions must be electronic. These are workflow considerations but not barriers — every telehealth platform should support PDMP integration and e-prescribing.

California, Illinois, and Pennsylvania generally follow federal guidelines without adding extra state-level telehealth restrictions. But all require PDMP checks (best practice even if not always legally mandated for stimulants) and e-prescribing.

Reimbursement: Will You Get Paid?

Yes. Telehealth payment parity for mental health is nearly universal in 2026. Almost every state has either enacted parity laws or insurers have voluntarily aligned rates — you get paid the same for a virtual med check as an in-person visit.

Medicare pays psychiatrists around:

• $89-95 for a 15-minute follow-up (CPT 99213)
• $125-136 for a 25-minute visit (CPT 99214)
• ~$190 for an initial psychiatric evaluation (CPT 90792)

These rates apply whether you’re seeing the patient in your office or via video.

Commercial insurance typically pays equal to or higher than Medicare — often 10-30% more depending on the plan.

Medicaid pays less (roughly $40-65 for a med check in most states), but volume can make it viable, especially in telehealth where overhead is low.

Psychiatrists get higher reimbursement than other provider types for the same services — your MD/DO license commands the top rate. Many insurers pay NPs at 85% of physician rates (though some credential NPs at full rates in mental health).

The economics work: A psychiatrist doing four 15-minute ADHD med checks per hour at Medicare rates grosses ~$360-400/hour. With telehealth, you eliminate commute time, office overhead, and often reduce no-shows — your net income per hour of clinical work can actually be higher than traditional practice.

What About the ADHD Medication Shortage?

It’s real and ongoing. Since late 2022, shortages of Adderall and other stimulants have disrupted care nationwide. The DEA has had to raise manufacturing quotas multiple times, but supply issues persist.

As a prescriber, this means:

• You’ll field patient frustration about pharmacy stockouts
• You may need to prescribe alternative medications (Vyvanse, generic methylphenidate, non-stimulants)
• Building relationships with multiple pharmacies helps
• Some patients may need to call several pharmacies to fill prescriptions

This isn’t a telehealth-specific problem — in-person providers face the same challenges. But it’s a reality of ADHD practice in 2026. Be prepared to be flexible with medication choices and educate patients that supply issues are industry-wide, not a reflection of your prescribing.

Compliance and Best Practices: Avoid the ‘Pill Mill’ Label

Telehealth ADHD prescribing came under scrutiny after some online companies overprescribed stimulants with minimal oversight. Done Health, Cerebral, and others faced investigations for inappropriately distributing controlled substances through brief questionnaires rather than proper evaluations.

How to stay compliant and protect your license:

1. Conduct thorough evaluations: Use DSM-5 criteria for ADHD. Employ standardized rating scales (ASRS for adults, Vanderbilt for children). Document symptom history, functional impairment, and rule out other conditions.

2. Check the PDMP every time (or at minimum, every 90 days for ongoing patients). Most states require it; even where optional, it’s essential to spot red flags like overlapping prescriptions or doctor shopping.

3. Obtain informed consent that covers stimulant risks, potential for misuse, and your monitoring plan. Document this.

4. Schedule regular follow-ups — monthly is standard for Schedule II medications. Monitor symptoms, side effects, vital signs, and adherence.

5. Coordinate with primary care when appropriate, especially for patients with cardiac history or other medical conditions affected by stimulants.

6. Consider urine drug screens if you have concerns about diversion or substance use — not routine for every patient, but a tool when clinically indicated.

7. Document everything. Your telehealth notes should be as thorough as in-person notes: patient location (for licensing compliance), consent, clinical findings, rationale for medication choice and dose, PDMP check, and plan.

The standard is simple: telehealth ADHD care should meet the same standard as in-person care. Florida’s telehealth law explicitly states this, and it’s the expectation everywhere. If you practice conservatively and document well, you’re protected.

Where the Demand Is: State Market Insights

Some states offer particularly strong opportunities for ADHD telehealth providers:

Texas and Florida face severe psychiatrist shortages — roughly 1 psychiatrist per 9,000 residents, well below the national average. Rural and suburban areas in both states have massive unmet need. However, TX’s NP restrictions mean psychiatrists are especially valuable there.

Pennsylvania and Illinois have moderate supply in cities (Philadelphia, Pittsburgh, Chicago) but rural shortages. Illinois’s NP full practice authority is increasing provider availability, but demand still exceeds supply.

New York has the best psychiatrist-to-population ratio (~1:2,900) thanks to NYC, but upstate and rural Long Island have gaps. NYC is competitive, but the sheer volume of patients seeking care (especially adult ADHD post-pandemic) keeps caseloads full.

California has high demand across the board — urban, suburban, and rural. The state is actively investing in mental health workforce expansion. With 40 million residents and progressive telehealth laws, CA offers scale.

In every state, adult ADHD diagnosis and treatment surged during the pandemic and hasn’t slowed. Patients who found it easier to seek help online have stayed online. You won’t struggle to fill your schedule — the challenge is managing volume while maintaining quality.

The Economics: Why Telehealth ADHD Care Makes Sense

Let’s talk about the business case, because that’s what matters when you’re deciding whether to add telehealth ADHD services or join a platform.

Traditional patient acquisition is expensive and uncertain. If you’re trying to build a practice through SEO, Google Ads, or directory listings:

• SEO takes 6-12 months of consistent investment before generating meaningful traffic
• Google Ads for mental health keywords cost $15-40+ per click, and most clicks don’t convert. Realistically, you’re paying $200-400+ per booked patient after factoring in click costs, ad testing, and lead qualification
• Directory listings (Psychology Today, Zocdoc) charge monthly fees and you compete with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booked appointment, plus monthly subscription fees
• Agency/consultant fees add thousands monthly if you’re outsourcing marketing
• Staff time to handle leads, qualify patients, and manage no-shows from cold leads adds hidden costs

When you factor in all of these costs — ad spend, failed campaigns, months of investment with no return, staff time, no-shows from unqualified leads — acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ each. And that’s if you have the marketing expertise, budget, and patience to make it work.

Platforms like Klarity remove that entire risk. Instead of gambling thousands on marketing channels that might not work, you pay only when a qualified patient books with you. No upfront marketing spend. No monthly subscription fees you’re paying whether you see patients or not. No wasted ad spend on clicks that don’t convert.

The platform handles patient acquisition, matching, credentialing, scheduling, and often billing infrastructure — you just show up for the clinical work. For many providers, especially those starting out or scaling, that’s a guaranteed ROI versus the uncertainty of DIY marketing.

Think of it this way: Would you rather spend $3,000-5,000/month on marketing with uncertain results, or pay per appointment with pre-qualified patients already matched to your availability and specialty?

For most providers, the answer is obvious.

What to Watch in 2026: Regulatory Uncertainty Ahead

The biggest question mark: What happens to federal telehealth controlled substance rules after December 2025?

Congress has extended the COVID-era flexibility three times. The current extension expires at the end of 2025. Options for 2026:

1. Another extension (likely, given bipartisan support for telehealth access)
2. Permanent legislation making telehealth prescribing allowable with certain safeguards (DEA has proposed a ‘special registration’ pathway, though details are unclear)
3. Reversion to Ryan Haight requirements (requiring in-person exams for new controlled substance patients)

If option 3 happens, telehealth ADHD practices would need to either:

• Partner with local clinics to provide initial in-person visits
• Focus only on established patients (those you’ve seen in-person at least once)
• Limit prescribing to non-controlled ADHD medications (atomoxetine, clonidine, etc.)

What to do now: Practice compliantly, stay informed on DEA announcements, and build flexibility into your practice model. Most experts expect some form of extension or permanent solution — cutting off telehealth controlled substance prescribing would massively disrupt access to mental health care nationwide.

But don’t assume anything. Follow the American Psychiatric Association, American Telemedicine Association, and your state medical board for updates.

Frequently Asked Questions

Can I prescribe Adderall on the first telehealth visit?Yes, under current federal rules (through December 2025). Conduct a thorough evaluation, document your clinical reasoning, check the PDMP, and prescribe via e-prescribing. However, some platforms or institutions have internal policies requiring additional steps — check with your employer or platform.

Do I need to see ADHD patients in-person periodically?Not under federal law currently. Some state medical boards or insurers may have recommendations (e.g., Medicare suggests periodic in-person visits for complex patients), but there’s no hard requirement as of early 2026. Practice standards suggest following up regularly via video for medication management.

Can I prescribe across state lines via telehealth?Only if you’re licensed in the state where the patient is physically located. You need a valid medical license in that state and DEA registration listing that state. Interstate compacts (like the Interstate Medical Licensure Compact) make multi-state licensing easier but don’t eliminate the requirement.

What if I’m a PMHNP in Texas — can I work around the Schedule II restriction?Not easily. Some NPs partner with a psychiatrist who writes the stimulant prescriptions while the NP manages other aspects of care (therapy, care coordination, non-stimulant meds). But you cannot independently prescribe Adderall or similar drugs in routine outpatient Texas practice.

How do I handle ADHD medication shortages?Build a list of alternative medications (different stimulant brands, long-acting vs short-acting, non-stimulants). Educate patients early that shortages are nationwide. Sometimes having patients try multiple pharmacies (chains vs independents) helps. Some providers also maintain relationships with specific pharmacies that tend to have better stock.

Will insurance pay for telehealth ADHD medication management?Yes. Nearly every major insurer now covers telehealth mental health visits at parity with in-person. This includes Medicare, Medicaid, and commercial plans. Make sure you’re credentialed with the payers you want to work with, and use proper telehealth CPT codes and modifiers.

What’s the typical patient volume and income for telehealth ADHD providers?Highly variable, but established providers often see 15-25 patients per day in telehealth (mix of new evaluations and 15-minute med checks). At Medicare rates, a full day of 20 brief visits at ~$90 each = $1,800 gross revenue per day. Many telehealth providers work 3-4 clinical days/week and gross $250K-400K+ annually depending on payer mix and volume. Overhead is minimal (no office rent, lower malpractice premiums for some telehealth-only practices).

The Bottom Line

Psychiatrists can absolutely prescribe ADHD medication via telehealth in 2026 — you have the authority, the reimbursement is there, and the patient demand is massive.

PMHNPs can in most states, though you need to know your state’s scope of practice and whether you’ll need physician collaboration.

The regulatory environment is mostly favorable but evolving. Federal telehealth flexibilities remain in place through 2025, and most observers expect some form of extension or permanent policy allowing controlled substance prescribing via telemedicine.

State-specific rules matter more for NPs than MDs, but all providers need to ensure licensing, PDMP compliance, and adherence to prescribing best practices.

Telehealth ADHD care is clinically sound, financially viable, and desperately needed. Providers who practice responsibly, document well, and stay current with regulations will find this an incredibly rewarding niche.

Ready to start seeing ADHD patients via telehealth? Platforms like Klarity Health connect you with pre-qualified patients, handle the administrative burden, and let you focus on clinical care — all with a pay-per-appointment model that eliminates marketing risk and upfront costs. Instead of spending thousands on uncertain marketing channels, you pay only when qualified patients book with you. No monthly subscription fees. No wasted ad spend. Just guaranteed patient flow and straightforward economics.

If you’re a psychiatrist or PMHNP looking to expand your practice or transition to telehealth, explore Klarity’s provider network to see how you can start building a sustainable, flexible ADHD practice today.

Sources and References

The information in this article is based on current regulations and policies as of February 2026. All sources have been verified for accuracy and currency. Regulatory statements are supported by official state statutes, federal agency guidance, and authoritative healthcare policy sources.

Top 5 Key Citations:

1. DEA & HHS Extension of COVID-Era Telehealth Prescribing (November 2024): The Drug Enforcement Administration and Department of Health & Human Services extended pandemic-era flexibilities allowing telehealth prescribing of controlled substances through December 31, 2025 — the third temporary extension of these rules. Source: Axios Healthcare Policy, November 18, 2024

2. Florida Telehealth Statute § 456.47 (2023): Florida law explicitly permits telehealth providers to prescribe Schedule II controlled substances when prescribed for psychiatric disorders, distinguishing mental health treatment from other controlled substance prescribing restrictions. Source: Florida Statutes, 2023 Edition

3. ADHD Prescription Surge Data (January 2024): Prescriptions for ADHD treatments surged 30% for adults aged 22-44 between 2020-2022, according to FDA researchers, reflecting increased demand during and after the pandemic. Source: Associated Press / JAMA Psychiatry, January 10, 2024

4. State-by-State NP Prescribing Authority (December 2025): Comprehensive analysis of nurse practitioner prescriptive authority by state, including restrictions on Schedule II controlled substances and collaborative agreement requirements. Source: RxAgent NP Authority Guide, Updated December 28, 2025

5. Telehealth Payment Parity Status (2024): Telehealth reimbursement parity for mental health services is nearly universal across U.S. states as of 2024-2026, with 48 states having enacted parity laws or policies requiring equal payment for virtual and in-person psychiatric services. Source: BehaveHealth Industry Analysis, 2024

Additional References:

• Texas Senate Bill 2527 Analysis (88th Legislature, 2023): Discussion of telehealth prescribing concerns and regulatory oversight of controlled substances via telemedicine platforms. Texas Legislature Bill Analysis

• Florida Statutes § 464.012 (Nurse Practice Act): Details on APRN prescribing authority, including 7-day limit on Schedule II drugs and psychiatric nurse exception allowing longer prescriptions for mental health treatment. Florida Online Sunshine

• Center for Connected Health Policy (CCHP) State Telehealth Laws: Comprehensive compilation of state-by-state telehealth regulations, including controlled substance prescribing rules for Texas, Florida, and other states. Updated January 2026

• Psychiatrist Workforce Data by State (2026): Analysis of psychiatrist-to-population ratios across U.S. states, identifying shortage areas and workforce distribution patterns. Healing Psychiatry Florida, January 15, 2026

• Medicare Reimbursement Rates for Psychiatric Services (2024-2025): Detailed CPT code reimbursement data for psychiatrists, including E/M codes (99213, 99214) and psychiatric evaluation codes (90792), showing Medicare, Medicaid, and commercial insurance payment rates. Therathink Practice Management, 2026 Edition

• Axios Policy Briefs on Telehealth & ADHD Medications (2024): Multiple reports covering DEA policy extensions, ADHD medication shortages, and Congressional action on telehealth controlled substance prescribing. Axios Healthcare Coverage, September-November 2024

All regulatory statements regarding state scope of practice, prescribing authority, and telehealth laws have been verified against official state statutes and board regulations current as of February 2026. Federal policy information reflects DEA and HHS guidance through the most recent published extensions. Clinical practice recommendations are consistent with American Psychiatric Association guidelines and standard psychiatric care protocols.

Note: Telehealth controlled substance prescribing rules remain subject to change pending federal action in 2026. Providers should monitor DEA announcements and consult with their state medical boards for the most current requirements.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the